三生国健2024年净利大增139%，90后牛红梅上任财务负责人、曾任职安永

Core Insights - The company reported a revenue of 1.194 billion yuan for 2024, representing a year-on-year growth of 17.7% [1] - The net profit attributable to shareholders reached 705 million yuan, showing a significant increase of 139.15% compared to the previous year [1][2] - The net cash flow from operating activities was 281 million yuan, which is a decline of 32.48% year-on-year [1] Financial Performance - The substantial increase in net profit is attributed to steady sales growth and a one-time special dividend distribution of 411 million yuan from the affiliated company Numab, which was included in the 2024 investment income [2] - The company has experienced a notable rise in sales revenue, contributing to the overall profit growth [2] Management Changes - The company announced that Sun Yongzhi will no longer serve as the financial head due to job relocation but will continue as a board member [2] - Niu Hongmei has been appointed as the new financial head, effective from the date of the board's approval until the current board's term ends [2] - Huang Haomin, a core technical staff member, has resigned from all positions within the company due to job relocation, while Gu Jinming has been recognized as a core technical personnel based on his experience and involvement in R&D projects [2][3] Key Personnel Background - Niu Hongmei, born in March 1990, holds a bachelor's degree in business administration and has experience in auditing and financial management within the company [3] - Gu Jinming, born in 1976, has a Ph.D. in molecular biology and extensive experience in R&D roles across various pharmaceutical companies [3]